HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer Intervention: Drug: HS-20089 Sponsor: Hansoh BioMedical R&D Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer Recurrent Interventions: Drug: IN10018; Drug: Placebo of IN10018; Drug: Pegylated Liposomal Doxorubicin Sponsor: InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer Intervention: Drug: HS-20089 Sponsor: Hansoh BioMedical R&D Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer Recurrent Interventions: Drug: IN10018; Drug: Placebo of IN10018; Drug: Pegylated Liposomal Doxorubicin Sponsor: InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer Intervention: Drug: HS-20089 Sponsor: Hansoh BioMedical R&D Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer Recurrent Interventions: Drug: IN10018; Drug: Placebo of IN10018; Drug: Pegylated Liposomal Doxorubicin Sponsor: InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer Intervention: Drug: HS-20089 Sponsor: Hansoh BioMedical R&D Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer Recurrent Interventions: Drug: IN10018; Drug: Placebo of IN10018; Drug: Pegylated Liposomal Doxorubicin Sponsor: InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer Intervention: Drug: HS-20089 Sponsor: Hansoh BioMedical R&D Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer Recurrent Interventions: Drug: IN10018; Drug: Placebo of IN10018; Drug: Pegylated Liposomal Doxorubicin Sponsor: InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer Intervention: Drug: HS-20089 Sponsor: Hansoh BioMedical R&D Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer Recurrent Interventions: Drug: IN10018; Drug: Placebo of IN10018; Drug: Pegylated Liposomal Doxorubicin Sponsor: InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer Intervention: Drug: HS-20089 Sponsor: Hansoh BioMedical R&D Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer Recurrent Interventions: Drug: IN10018; Drug: Placebo of IN10018; Drug: Pegylated Liposomal Doxorubicin Sponsor: InxMed (Shanghai) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer Intervention: Drug: HS-20089 Sponsor: Hansoh BioMedical R&D Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials